Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-09-08
|
aducanumab (BIIB037) |
Alzheimer's disease |
3 |
Biogen (USA - MA) |
Neurodegenerative diseases |
2015-09-08
|
aducanumab (BIIB037) |
Alzheimer's disease |
3 |
Biogen (USA - MA) |
Neurodegenerative diseases |
2015-09-08
|
FPA008 (cabiralizumab) and Opdivo® (nivolumab) |
non-small cell lung cancer, melanoma, head and neck squamous cell cancer, pancreatic cancer, colorectal cancer, glioblastoma multiforme |
1 |
Five Prime Therapeutics (USA - CA) BMS (USA - NY) |
Cancer - Oncology |
2015-09-08
|
CER-001 |
acute coronary syndromes |
2 |
Cerenis Therapeutics (France) |
Cardiovascular diseases |
2015-09-08
|
VTS-270 - 2-hydroxypropyl-?-cyclodextrin |
Niemann-Pick disease type C1 |
2b-3 |
Sucampo Pharmaceuticals (USA - MA) |
Rare diseases - Genetic diseases |
2015-09-08
|
89Zr-Df-IAB2M |
prostate cancer |
2 |
ImaginAb (USA - CA) |
Cancer - Oncology - Technology - Services |
2015-09-08
|
bavituximab |
|
|
Peregrine Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2015-09-08
|
RHB-105 (amoxicillin, rifabutin and omeprazole) |
Helictobacter pylori infection |
3 |
RedHill Biopharma (Israel) |
Infectious diseases |
2015-09-07
|
vintafolide |
folate receptor (FR) positive recurrent non-small cell lung cancer (NSCLC) |
2b |
Endocyte (USA - IN) |
Cancer - Oncology |
2015-09-07
|
Opdivo® (nivolumab) |
advanced, squamous cell non-small cell lung cancer (NSCLC) |
3 |
BMS (USA - NY) |
Cancer - Oncology |
2015-09-07
|
Opdivo® (nivolumab) |
advanced squamous cell non-small cell lung cancer |
2 |
BMS (USA - NY) |
Cancer - Oncology |
2015-09-07
|
ALLOB® |
delayed union fractures |
1-2a |
Bone Therapeutics (Belgium) |
Bone diseases - Regenerative medicine |
2015-09-03
|
GBR 830 |
atopic dermatitis |
1 |
Glenmark Pharmaceuticals (India) |
Autoimmune diseases - Immunological diseases - Dermatological diseases |
2015-09-02
|
AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) |
Hurler syndrome or mucopolysaccharidosis type I (MPS I) |
1 |
Armagen (USA - CA) |
Rare diseases - Genetic diseases |
2015-09-02
|
fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) |
HIV-1 infection |
3 |
Gilead (USA - CA) |
Infectious diseases |
2015-09-02
|
CTL019 - tisagenlecleucel-T |
chronic lymphocytic leukemia (CLL) |
|
University of Pennsylvania (USA - PA) Novartis (Switzerland) |
Cancer - Oncology |
2015-09-02
|
DCR-PH1 - synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene |
primary hyperoxaluria type 1 (PH1) |
1 |
Dicerna Pharmaceuticals (USA - MA) |
Rare diseases - Genetic diseases - Kidney diseases |
2015-09-01
|
Praluent™ (alirocumab - SAR236553/REGN727) |
patients with hypercholesterolemia who are at high or very-high cardiovascular (CV) risk, including patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) |
3 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
Cardiovascular diseases - Genetic diseases - Rare diseases |
2015-09-01
|
MEDI9197 |
solid tumors |
1 |
MedImmune (USA - global biologics arm of AstraZeneca (UK) |
Cancer - Oncology |
2015-09-01
|
triheptanoin (UX007) |
cardiomyopathy due to long-chain fatty acid oxidation disorders (LC-FAOD) |
|
Ultragenyx Pharmaceutical (USA - CA) |
Rare diseases - Cardiovascular diseases |